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A B S T R A C T
Recent prospective controlled studies have demonstrated that transcatheter closure of a patent foramen
ovale (PFO) reduces recurrent stroke risk in select patients, especially in patients younger than 60 years
with PFO and embolic-appearing infarct and where no other mechanism of stroke was identified.
Detection of PFO depends on the intensity of the Valsalva maneuver, and not all PFOs can be diagnosed
using transesophageal echocardiography. Transthoracic contrast echocardiography using abdominal
compression during the Valsalva maneuver is an easy method that can increase the detection sensitivity
of PFO shunt. PFO with two or more of the following factors is most likely considered a “high-risk PFO”
and as such, has a significantly higher probability of cryptogenic stroke: (1) a long-tunnel PFO (10 mm
in length), (2) atrial septal aneurysm and/or hypermobile interatrial septum, (3) prominent Eustachian
valve or Chiari’s network, (4) large right-to-left shunt at rest and during the Valsalva maneuver, and (5)
low-angle PFO. In order to establish the benefit of catheter-based PFO closure as a safe and effective
treatment in clinical practice, the degree of accuracy of PFO diagnosis and its long-term safety need to be
confirmed.
© 2020 Published by Elsevier Ltd on behalf of Japanese College of Cardiology. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Recently published long-term data from randomized controlled
trials have provided evidence for the prevention of recurrent
embolic stroke of an undetermined source by percutaneous
closure of patent foramen ovale (PFO) [1]. Three prospective
controlled studies published in 2017 demonstrated that transcath-
eter closure of PFO significantly reduced the risk of recurrentE-mail address: t-akagi@cc.okayama-u.ac.jp.
https://doi.org/10.1016/j.jjcc.2020.09.005
0914-5087/© 2020 Published by Elsevier Ltd on behalf of Japanese College of Card
creativecommons.org/licenses/by-nc-nd/4.0/).paradoxical cerebral embolism compared with conventional
antithrombotic therapy alone [2–4]. In Japan, transcatheter PFO
closure has been approved as health insurance medical treatment
since December 2019, and this procedure is gaining attention as a
new therapeutic option for stroke prevention in young adults [5].
In 2020, the American Academy of Neurology reviewed previous
criteria and stated that PFO closure probably reduces recurrent
stroke risk in select patients, especially in patients younger than
60 years with a PFO and embolic-appearing infarct and where no
other mechanism of stroke was identified. At the same time, the
statement demonstrated that clinicians may recommend PFOiology. This is an open access article under the CC BY-NC-ND license (http://
T. Akagi / Journal of Cardiology 77 (2021) 3–94closure following a discussion of potential benefits (absolute
recurrent stroke risk reduction of 3.4% at 5 years) and risks
(periprocedural complication rate of 3.9% and increased absolute
rate of non-periprocedural atrial fibrillation of 0.33% per year) [6].
Therefore, in order for this treatment to be widely accepted in the
future, it is important that the procedure is carried out safely and
appropriate patient selection is carried out by a team composed of
cardiologists and stroke specialists. Diagnosis and morphological
evaluation of PFO, both of which have received little attention in
the past, have become important tasks for cardiologists. Further-
more, there are many new issues that should be addressed in the
future, including the expansion of therapeutic indications and
introduction of a new closure system.
What is PFO?
The foramen ovale is an intracardiac structure essential for fetal
circulation. After birth, pulmonary circulatory blood flow and left
atrial pressure increase meaning that most foramen ovale
functionally close within a few days to several months after birth.
However, when the primary septum and secondary septum around
the foramen ovale are not completely fused, the flap becomes a
one-way flap, and a right-left shunt occurs when the right atrial
pressure exceeds the left atrial pressure. Such a condition is called
PFO and is reported to occur in about 15%–25% of general healthy
adults [7–9]. Subsequently, if a venous thrombus passes through a
PFO, flows into the left side heart chamber, and reaches the cranial
arterial system, a paradoxical cerebral embolism develops [10].
Relationship between PFO and cryptogenic stroke
It has been previously reported that when a venous thrombosis
flows into the left heart system through the foramen ovale,
embolism of systemic arteries, such as cerebral infarctions, can
occur [10]. However, diagnosis of PFO is difficult, so much so that
the existence of the PFO was only recognized only with the spread
of transesophageal echocardiogram use. The importance of PFO
diagnosis as a cause of cerebral infarction has increased,
specifically because PFO is found more frequently in younger
patients with paradoxical cerebral embolism than in healthy
subjects of the same age [11]. It was initially demonstrated that the
incidence of PFOs was significantly higher in a group of patients
with paradoxical embolism who were relatively young (55 years)
than in a non-cerebral infarction group of the same age. It is
suggested that a considerable number of cases of cerebral
infarction associated with PFO may exist in the elderly (355
years old) [12]. Therefore, when thromboembolism is suspected
neuroradiologically, it is necessary to estimate the possibility of a
paradoxical brain embolism due to PFO. However, in actual clinical
settings, when PFO is found in a patient with a cerebral embolism,
it may be difficult to determine whether the cerebral embolism
was caused by a thromboembolism derived from a PFO or whether
the PFO was incidentally detected [13]. To determine that PFO has
caused a cerebral embolism, it is necessary to prove the following
4 factors: (1) proof of cerebral embolism due to thromboembolism
by image diagnosis such as magnetic resonance imaging (MRI)
with diffusion-weighted imaging; (2) absence of cerebral embo-
lism sources other than PFO (atrial fibrillation, left atrial
appendage thrombosis, carotid plaque, and so on); (3) detection
of deep vein thrombosis or pulmonary embolism; (4) presence of
PFO through which the thrombus passes. Therefore, PFO-related
paradoxical cerebral infarction is confirmed by diagnosis of
exclusion in current clinical settings [1]. However, it is often
difficult to evaluate deep vein thrombosis after anticoagulant
therapy prior to evaluation by a cardiologist. It is reported that
around 5% of patients with cerebral infarctions have a cerebralembolism caused by PFO, even when such strict diagnostic criteria
are applied [14]. The risk of cerebral infarction in healthy adults
with PFO is estimated to be 0.1% per year, but the actual annual
recurrence rate of paradoxical cerebral embolism is reported to be
between 3.4% and 11% [15]. Therefore, it is considered that
additional factors must be included in order for a PFO to be the
etiology of a cerebral infarction.
Transcatheter PFO closure
Up to now, antiplatelet therapy or anticoagulant therapy has
been recommended to prevent cerebral infarction recurrence in
patients with paradoxical embolism. However, comparison of
anticoagulation therapy and antiplatelet therapy to date has not
supported the benefit of anticoagulation therapy [16]. Continuing
lifelong anticoagulation therapy for young adults presents
difficulties with regard to drug adherence. If cryptogenic stroke
develops due to a thromboembolism passing through PFO,
transcatheter closure of PFO may contribute to the reduction of
cryptogenic stroke recurrence. For this reason, several control
studies on transcatheter closure of PFOs have been undertaken to
clarify the efficacy of cryptogenic stroke reoccurrence prevention
[17,18]. However, in a control study that compared the effective-
ness of catheter closure and drug therapy as secondary prevention
of paradoxical cerebral embolism, it has taken a long time to
confirm the effectiveness of catheter closure in comparison to
anticoagulation therapy [2–4]. In the RESPECT study that utilized
the Amplatzer PFO occluder (Abbott, St. Paul, MN, USA) (Fig. 1),
980 patients were enrolled, and the study was continued until
25 cerebral infarction recurrences were confirmed. Initially, the
intention-to-treat analysis showed that the catheter closure group
had a 50.8% risk reduction ratio compared to the anticoagulation
treatment group; however, it did not reach statistical significance
[17]. However, after a longer follow-up, a significant reduction of
the recurrent stroke ratio was confirmed in the intention-to-treat
analysis. Furthermore, when patients who had a known cause of
recurrent stroke other than PFO were excluded, transcatheter
closure was clearly shown to be more effective than anticoagulant
treatment for preventing the recurrence of paradoxical cerebral
embolism [2]. In other words, it was confirmed that transcatheter
PFO closure had no preventive effect on cerebral infarctions not
associated with PFO (such as lacuna infarction or thromboembo-
lism due to left heart system thrombosis). Additionally, this study
could demonstrate that the incidence of new onset of atrial
fibrillation was not increased in the PFO closure group compared
with the control group, and the risk of new onset of atrial
arrhythmia due to device implantation was low. Based on these
results, the Amplatzer PFO occluder was officially approved for the
prevention of recurrent paradoxical cerebral embolism in 2016. In
2017, the REDUCE study using the Gore Septal Occluder (Gore,
Flagstaff, AZ, USA) reported that catheter closure significantly
reduced the cerebral infarction recurrence rate compared with
medical therapy and further reduced the incidence of asymptom-
atic cerebral infarctions observed on follow-up MRI studies [3].
Diagnostic process of PFO
In patients suspected of having paradoxical cerebral embolism,
a transthoracic echocardiography, transcranial Doppler study, and
transesophageal echocardiography using contrast bubble injection
are indicated. Diagnosis of a large PFO that presents with an atrial
septal aneurysm or left to right shunt on color Doppler at rest is
relatively easy. However, the majority of PFOs cannot be detected
at rest and a contrast bubble study using the strong Valsalva
maneuver is essential. Normally, left atrial pressure is a few mmHg
higher than right atrial pressure; however, during or just after the
Fig. 1. Patent foramen ovale shunt grading by a transthoracic echocardiographic bubble study. Grade 1 (fewer than 5 bubbles), Grade 2 (6–25 bubbles), Grade 3 (25 or more),
and Grade 4 (visualization of the entire heart chamber).
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higher than left atrial pressure, and right-left shunt can be detected
more clearly. In this regard, transesophageal echocardiographic
evaluation under regular sedation may not detect PFO shunt as the
Valsalva maneuver is not sufficient for detection [1,16]. The
sensitivity of PFO detection depends on the intensity of the
Valsalva maneuver, and not all PFOs can be diagnosed by using
transesophageal echocardiography. In particular, during transeso-
phageal echocardiography with deep sedation, the sensitivity of
PFO detection decreases significantly. Therefore, transthoracic
contrast echocardiography with a sufficient Valsalva maneuver has
been reconsidered as a screening test for PFO detection [16]. A
recent report described that manual abdominal compression
during the Valsalva maneuver is an easy method of increasing the
detection sensitivity of PFO [19]. There are several evaluation
criteria for the bubble test, and it is common for the test results to
be deemed positive when contrast is either found in the left atrium
after fulfilling the right atrium or within 3 heartbeats after the
Valsalva maneuver is released. If contrast appears in the left atrium
after 3 heartbeats, pulmonary shunting due to a pulmonary
arteriovenous fistula is suspected. Shunt grades are classified into
Grades 1–4 according to the amount of bubbles detected in the left
heart system. In the case of Grade 1 (fewer than 5 bubbles in the
left heart system) to Grade 2 (6–25 bubbles), morphological
evaluation by transesophageal echocardiography is required
because it may be a false positive finding. Grade 3 (25 or more)
and Grade 4 (visualization of the entire heart chamber) strongly
suggest the presence of a PFO (Fig. 1) [5]. When the presence of aPFO is suspected following a contrast echo study, morphological
evaluation by transesophageal echocardiography, that is, PFO
height, tunnel length, and atrial septal aneurysm are evaluated
[20]. At the same time, the presence of the Eustachian valve and the
Chiari network, which direct venous thrombosis in the lower
extremities toward the foramen ovale, should be evaluated. In
addition, if right-left shunting is observed before the Valsalva
maneuver, the PFO can be considered as high risk for paradoxical
embolism [21].
Step-by-step procedure for transcatheter PFO closure
The Amplatzer PFO device is currently the only PFO device
available in Japan. Internationally, the Gore PFO device and the
Occlutech PFO device (Helsingborg, Sweden) are also available for
PFO closure. The catheter closure itself is similar to the catheter
closure for atrial septal defect (ASD) currently used in Japan. In
cases with transesophageal echocardiographic monitoring, the
procedure is performed under general anesthesia, and with local
anesthesia or deep sedation in cases that require intracardiac
echocardiography monitoring (Figs. 2 and 3). Balloon sizing of the
defect hole is recommended for ASD catheter treatment, however
for PFO closure, the optimal device is selected according to PFO
morphology such as the presence or absence of a septal aneurysm
and thickness of septal secundum. When using the Amplatzer PFO
device, the 25-mm device is selected in a majority of cases;
however, for patients who have a large septal aneurysm (>20 mm)
or significantly thicker septum secundum (>10 mm), a 35-mm
Fig. 2. (A) Intracardiac echocardiographic finding of PFO closure. Both side disks are placed in an appropriate position. (B) Fluoroscopic findings of PFO device implantation.
PFO, patent foramen ovale.
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day) or anticoagulant therapy started prior to PFO closure should
also be continued at least 6 months after PFO closure [2]. For
discontinuation of antiplatelet or anticoagulation therapies,
discussion with stroke specialists is recommended and is
dependent on each individual patient’s comorbidities or condition.
Transient atrial arrhythmias may be associated with catheter
procedures, guidewires, or mechanical irritation of the device itself
during or immediately after device implantation. However, atrial
fibrillation, which requires additional medical management, was
rarely noted during the long-term follow-up period and the
incidence of new atrial fibrillation was similar to that of the age-
matched normal population.What is a high-risk PFO?
Previous studies have demonstrated that the morphological
characteristics of PFO are strongly associated with the risk of
cryptogenic stroke. In particular, the presence of atrial septal
aneurysms, PFO with a large right-left shunt, and long-tunnel
PFO are considered to be strongly associated with paradoxical
embolism. Thus, in the past, controlled studies have focused on
patients with a large shunt and/or PFO with atrial septal
aneurysms. Recently, a retrospective study that combined two
studies (CLOSE trial and DEFENCE trial) assessed whether the
presence of atrial septal aneurysms or the degree of shunting
was associated with cerebral infarction recurrence [20]. The
Fig. 3. (A) Intracardiac echocardiographic findings after deployment. (B) Fluoroscopic findings after patent foramen ovale closure.
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more important than the degree of shunting with regard to
stroke recurrence. As previously mentioned, the degree of
shunting depends on the strength of the Valsalva maneuver
and is underestimated if the Valsalva maneuver is insufficient,
which occurs in transesophageal echocardiographic studies
performed under sedation. It is considered that quantitative
evaluation of the degree of shunting is not always suitable
for the evaluation of paradoxical embolism risk. On the other
hand, the presence of an atrial septal aneurysm can be
objectively diagnosed by using transesophageal echocardiogra-
phy, and PFOs with atrial septal aneurysms result in PFO with a
large degree of shunting and as such, have a high risk of
paradoxical embolism.To evaluate the characteristic features of PFO in patients with a
paradoxical embolism, we performed a transesophageal echocar-
diographic comparison between patients with cryptogenic stroke
and without stroke (migraine only). A comparison of transeso-
phageal echocardiographic findings between the two groups
revealed significant differences in PFO morphology. The following
five characteristics were frequently observed in patients with
cryptogenic stroke: (1) a long-tunnel PFO (10 mm in length); (2)
atrial septal aneurysm and/or hypermobile interatrial septum; (3)
prominent Eustachian valve or Chiari’s network; (4) large right-to-
left shunts at rest and during the Valsalva maneuver; and (5) low-
angle PFO (10 PFO angle from inferior vena cava), compared with
patients without cryptogenic stroke (Fig. 4). When the score was
estimated based on 1 point for each factor, a higher proportion of
Fig. 4. High-risk PFO characteristics. IVC, inferior vena cava; LA, left atrium; PFO, patent foramen ovale; RA, right atrium.
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without-stroke group. PFO with two or more factors should be
considered as “high-risk PFO” with a higher probability of
cryptogenic stroke as compared with PFOs presenting with fewer
than two of the aforementioned factors [21]. Although further
prospective evaluations are required, morphological evaluation of
PFO may provide important diagnostic information as to whether
PFO can be considered as the possible cause of cryptogenic stroke
or if it was incidentally observed. Such morphological and risk
assessments will provide important information not only for
determining therapeutic indications for the prevention of crypto-
genic stroke, but also for future indications for transcatheter PFO
closures for the primary prevention of cerebral infarctions.
Pathological conditions other than cryptogenic stroke and
future direction
Various pathological conditions related to PFO, other than
cryptogenic stroke, have been previously reported. It has been
reported that PFOs cause systemic peripheral arterial embolism
including acute myocardial infarction due to coronary artery
thromboembolic occlusion. In addition, cerebral infarctions due to
venous thrombosis associated with malignant tumors (Trousseau
syndrome) is also of clinical interest [22]. Furthermore, it has been
recently reported that cryptogenic stroke is frequently seen in
patients with COVID-19, and it has been suggested that hyperco-
agulability could be associated with this virus infection [23]. It has
been reported that when a rapid decompression occurs during
scuba diving, nitrogen gas dissolved in the blood bubbles may
cause cerebral embolism via the PFO [24]. Similarly, it has been
suggested that high altitude sickness caused by mountain climbing
is associated with the appearance of a right-left shunt due to
decreasing atmospheric pressure [25]. Platypnea-orthodeoxia
syndrome, which is often seen in the elderly, has no symptoms
in the supine position; however, severe cyanosis and dyspnea
appear when the upper body is elevated. In the standing position,the ascending aorta impairs blood flow returning from the inferior
vena cava into the right atrium, causing blood from the inferior
vena cava to flow directly into the left atrium passing through from
the PFO, causing severe cyanosis [26,27]. The association between
migraine headaches, especially migraine with aura, and PFO has
also gained scientific interest. Previous studies demonstrated that
about 50% of patients with migraine with aura have a PFO and that
patients with PFOs have migraine with aura at a rate 3.2 times
higher than those without PFO [28,29]. Up to now, three
prospective studies evaluated the therapeutic efficacy of PFO
catheter closure in patients with migraine who were not
responsive to conventional medical therapy [30–32]. However,
the clinical efficacy of catheter closure of PFOs has not been
confirmed for migraine headaches compared to medical manage-
ment. Further studies are required with inclusion criteria,
indication of treatment, and comparison with medical therapies
[33]. In order to establish the benefit of catheter-based PFO closure
as a safe and effective treatment for any clinical condition, accurate
PFO diagnosis and long-term safety need to be confirmed [6,34]. In
place of the currently used metal mesh closure system, a novel
closure system that does not leave any foreign matter inside the
body (such as a bioabsorbable material or absorbent thread) or a
radiofrequency energy adhesion system should be considered in
the future. PFO closure as a treatment modality is an exciting area
of research that has only just begun.
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